65.1% of treated children with sepsis and kidney injury survived 90 days, versus 47.4% in a comparison group.
SeaStar Medical (ICU) reported that its QUELIMMUNE (SCD-PED) treatment showed a 65.1% 90-day survival rate in pediatric sepsis patients, compared to 47.4% in a historical cohort. The data, presented at ASN Kidney Week 2026, also showed no device-related adverse events. The company's stock is traded on Nasdaq.
How this was made
The 30-second read
Why it matters
The disclosed survival benefit could accelerate adoption, drive future sales, and improve the company's valuation.
Market read
First public release of statistically significant efficacy data for ICU's flagship product, likely to move the stock.
What to watch
Reimbursement pathways and insurance coverage for the device could constrain commercial upside despite clinical success.
Background
SeaStar Medical (ICU) focuses on therapies for critically ill patients with organ failure. The QUELIMMUNE (SCD-PED) device received FDA approval earlier this year and is now being evaluated in real‑world post‑approval registries.
Ticker impact
SeaStar Medical announced positive late-breaking clinical data for its QUELIMMUNE (SCD-PED) therapy showing significantly higher 90‑day survival in pediatric sepsis‑associated AKI patients.
upward pressure as investors price in improved clinical outlook
First disclosure of statistically significant survival improvement; no prior public data, strong safety profile, and potential for expanded adoption.
Market effects
May boost sentiment for pediatric renal‑failure devices and broader renal‑replacement therapy sector.
Limited to US biotech/medical‑device investors; no broader regional effect.
Modest; relevance primarily to investors tracking innovative medical‑device pipelines.
Counterpoint
Skeptics may question the small sample size and lack of a randomized control, potentially limiting price upside.
Key entities
- companySeaStar Medical Holding Corp
US‑listed medical‑device company reporting the data.
- productQUELIMMUNE (SCD-PED)
Selective Cytopheretic Device for pediatric sepsis‑associated AKI.
